760 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by R Squared Ltd

R Squared Ltd bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 760 shares of the company’s stock, valued at approximately $64,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of AXSM. Northwestern Mutual Wealth Management Co. purchased a new position in Axsome Therapeutics during the second quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Axsome Therapeutics in the second quarter worth $47,000. KBC Group NV raised its position in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after buying an additional 385 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares during the period. Finally, Moors & Cabot Inc. purchased a new position in Axsome Therapeutics during the third quarter worth about $200,000. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $106.46 on Friday. The company has a market capitalization of $5.16 billion, a P/E ratio of -16.30 and a beta of 1.04. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The stock has a 50 day moving average price of $93.57 and a two-hundred day moving average price of $90.81.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the prior year, the business posted ($1.32) EPS. Analysts expect that Axsome Therapeutics, Inc. will post -4.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a report on Thursday, December 12th. HC Wainwright increased their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $139.00 price objective on shares of Axsome Therapeutics in a report on Wednesday. Robert W. Baird increased their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, Mizuho cut their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, December 31st. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $132.08.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.